What Happens When You Stop Taking Semaglutide (Ozempic, Wegovy)

Yes — in the randomized trials that have tested this directly, people regain a substantial share of the weight they lost after stopping semaglutide, on average. A meta-analysis of eight randomized controlled trials found that people who stopped a GLP-1 receptor agonist regained weight on average, and that the regain was proportional to how much they had originally lost ^[4]. In SURMOUNT-4, a tirzepatide withdrawal trial, participants who were switched from active drug to placebo regained an average of 14.0% of their body weight over the following year, while those who stayed on tirzepatide kept losing ^[3]. A second randomized withdrawal trial, STEP 4, tested the same question for semaglutide by comparing continued weekly injections against placebo for weight-loss maintenance ^[1].

The regain is not a sign that the drug failed or that the person lacked discipline. The same meta-analysis found that weight came back “regardless of lifestyle interventions,” and its authors concluded that GLP-1 receptor agonists should be considered chronic therapy to prevent regain ^[4]. These figures are group averages, though, and individual results vary widely — in SURMOUNT-4, 16.6% of people switched to placebo still kept at least 80% of their lost weight off a year later ^[3].

How much weight comes back, on average, after stopping?

The most complete pooled estimate comes from a systematic review and meta-analysis published in Obesity Reviews, which searched databases from inception through February 1, 2024, and retained 8 randomized controlled trials with 2,372 participants, all with a BMI of 27 kg/m² or higher ^[4]. The review extracted body weight, waist circumference, and BMI changes both on and off treatment ^[4].

The pooled numbers differ by drug:

Drug stopped	Pooled average weight regained	95% confidence interval
Liraglutide	2.20 kg	1.69 to 2.70 kg
Semaglutide or tirzepatide	9.69 kg	5.78 to 13.60 kg

Both results were statistically significant (P < 0.00001), and the reviewers reported that the proportion of weight regained was proportional to the amount originally lost ^[4].

What did the withdrawal trials actually show?

Two randomized trials have tested what happens when the drug is deliberately stopped.

The clearest picture comes from SURMOUNT-4, a tirzepatide trial — tirzepatide is a different drug from semaglutide, so its numbers are a close but not identical comparison. The trial ran at 70 sites in 4 countries. It began with a 36-week open-label lead-in, in which 783 adults with obesity, or overweight with a weight-related complication and no diabetes, received once-weekly tirzepatide at the maximum tolerated dose of 10 or 15 mg ^[3].

At week 36, the 670 participants who completed the lead-in (mean age 48, 473 of them women, mean weight 107.3 kg) had lost an average of 20.9% of their body weight. They were then randomized 1:1 — 335 to continue tirzepatide, 335 to switch to placebo — for a 52-week double-blind period ^[3].

Measure (weeks 36 to 88)	Continued tirzepatide	Switched to placebo
Mean weight change	−5.5%	+14.0%
Maintained ≥80% of lead-in weight loss	89.5% (300 participants)	16.6%
Total weight change, week 0 to 88	−25.3%	−9.9%

The difference between groups over the withdrawal year was −19.4 percentage points (95% CI −21.2 to −17.7, P < .001) ^[3]. The trial’s conclusion: withdrawing tirzepatide led to substantial regain of lost weight, whereas continued treatment maintained and augmented the initial reduction ^[3].

For semaglutide specifically, the STEP 4 trial compared continued weekly subcutaneous semaglutide against placebo for weight-loss maintenance in adults with overweight or obesity ^[1]. The STEP 1 trial extension, published in Diabetes, Obesity and Metabolism in 2022, examined weight regain and cardiometabolic effects after semaglutide withdrawal ^[2].

Does staying on semaglutide hold the weight off?

Yes, and the long-term trials show how large the gap is between staying on and stopping.

STEP 5 enrolled and randomized 304 adults between October 5, 2018 and February 1, 2019, assigning them to semaglutide 2.4 mg weekly (152 people) or placebo (152 people), both alongside behavioral intervention, and followed them for 104 weeks. Participants had a mean age of 47.3, a mean BMI of 38.5, and a mean weight of 106.0 kg ^[5]. At 104 weeks — two full years — the semaglutide group had lost an average of −15.2% of body weight versus −2.6% with placebo, a treatment difference of −12.6 percentage points (95% CI −15.3 to −9.8, P < 0.0001). Weight loss of at least 5% was achieved by 77.1% of the semaglutide group versus 34.4% of the placebo group ^[5].

The SELECT trial provides the longest randomized semaglutide weight data in the evidence reviewed here: 4 years, in 17,604 adults with preexisting cardiovascular disease and overweight or obesity, without diabetes. Weight loss continued over 65 weeks and was sustained for up to 4 years. At week 208, semaglutide was associated with a mean weight reduction of −10.2%, a waist circumference reduction of −7.7 cm, and a waist-to-height ratio reduction of −6.9%, versus −1.5%, −1.3 cm, and −1.0% with placebo (P < 0.0001 for all comparisons) ^[6]. In the same trial, semaglutide reduced major adverse cardiovascular events by 20% (hazard ratio 0.80, 95% CI 0.72 to 0.90) ^[6].

Why does the weight come back after stopping?

Semaglutide is a glucagon-like peptide-1 (GLP-1) analog, or receptor agonist. At a dose of 2.4 mg once weekly, subcutaneous semaglutide is approved for weight management in adults with obesity (BMI ≥30), or overweight (BMI ≥27) with at least one weight-related comorbidity ^[5], and it is described as approved for chronic weight management ^[6].

Weight-management medications work by modifying appetite ^[6]. The STEP 5 paper notes the other side of this: behavioral intervention built on diet and physical activity changes is the foundation of treatment, but on its own it has historically struggled to produce weight loss that is both clinically meaningful and durable — which is why pharmacotherapy is recommended as an additional long-term tool ^[5]. The SELECT paper makes the same point: producing and sustaining clinically significant weight loss with lifestyle intervention alone has been challenging, while medications that modify appetite can make attaining and sustaining such loss more likely ^[6].

That framing explains the regain data: the drug is doing work that lifestyle change alone has historically not been able to sustain, and the discontinuation meta-analysis therefore frames GLP-1 receptor agonists as chronic therapy rather than a short course ^[4].

What happened to blood sugar among people who stopped?

A real-world cohort study provides the closest published numbers, but it measured something narrower than a post-stop rise: how much HbA1c fell over one year, grouped by discontinuation status, among patients with prediabetes at baseline. The mean absolute HbA1c reduction at one year was 0.1 points for those who discontinued early, 0.2 points for those who discontinued late, and 0.4 points for those who did not discontinue (P < 0.001) ^[7]. In other words, the glycemic benefit tracked with staying on treatment. The study did not measure blood sugar rising after a stop, so no post-stop rise can be cited from it.

The STEP 1 trial extension examined cardiometabolic effects alongside weight regain after semaglutide withdrawal ^[2], but no blood pressure or lipid figures from it appear in the materials reviewed here, so no specific numbers for those measures can be cited.

What happens to people who stop outside of a trial?

A retrospective cohort study used electronic health record data from a large health system in Ohio and Florida to follow adults with overweight or obesity, without type 2 diabetes, who started injectable semaglutide or tirzepatide between 2021 and 2023. It identified 7,881 patients: 6,109 on semaglutide and 1,772 on tirzepatide, with follow-up through December 2024 ^[7].

Discontinuation was defined as a gap of more than 90 days between exhausting the previous supply and the next dispense. “Early” discontinuation meant within 3 months of starting; “late” meant between 3 and 12 months ^[7].

Discontinuation status	Mean 1-year weight reduction	Mean HbA1c reduction (prediabetes at baseline)
Early discontinuation	3.6%	0.1 points
Late discontinuation	6.8%	0.2 points
No discontinuation	11.9%	0.4 points

The overall average one-year weight reduction was 8.7%, and the differences by discontinuation status were significant (P < 0.001) ^[7]. Notably, 80.8% of this cohort were on low maintenance dosages, and the authors attributed the below-trial results to higher discontinuation rates and lower doses than in the phase 3 trials ^[7].

Are there withdrawal symptoms when you stop semaglutide?

None of the trials cited here describe a physical withdrawal syndrome from stopping semaglutide. The side effects these trials tracked were gastrointestinal events that occurred while taking the drug, not after stopping it.

In SURMOUNT-4, the most common adverse events were mostly mild-to-moderate gastrointestinal events, and they occurred more commonly with tirzepatide than with placebo ^[3]. In STEP 5, gastrointestinal adverse events, mostly mild-to-moderate, were reported in 82.2% of the semaglutide group versus 53.9% of the placebo group ^[5]. In SELECT, semaglutide was associated with fewer serious adverse events across every BMI category, but with increased rates of discontinuing the trial product — and those discontinuations rose as BMI class fell ^[6].

What the evidence does show happening after a stop is average weight regain across the pooled trials ^[4].

Is semaglutide a lifelong medication?

The longest randomized semaglutide weight data in the evidence reviewed here run 4 years. SELECT followed participants to week 208, and weight loss was sustained over that full period ^[6]. STEP 5, at 104 weeks, was described at publication as the longest semaglutide weight-management trial to date ^[5].

The discontinuation meta-analysis takes a position: because regain occurs regardless of lifestyle interventions, GLP-1 receptor agonists should be considered chronic therapy to prevent weight regain and the undesirable outcomes associated with obesity ^[4]. Whether an individual person stays on the drug indefinitely, switches treatments, or stops is a decision that depends on their own situation — and the meta-analysis authors recommend that the risk of regain be discussed with a clinician when stopping therapy ^[4].

What should I discuss with a prescriber before stopping?

The trials position obesity pharmacotherapy as an adjunct to diet, physical activity, and behavioral intervention — not a replacement for them [3, 5]. That framing matters for a stopping decision: the drug was one part of a package in every trial that showed benefit.

The real-world cohort data also show that dose level and persistence track with results — people who stayed on treatment lost more at one year, and the authors specifically credited lower maintenance doses, alongside discontinuation, for the gap between practice and trials ^[7].

Reasonable questions to bring to that conversation include: what the pooled regain data (an average of 9.69 kg across semaglutide and tirzepatide trials) would mean for your situation ^[4]; what diet, activity, and behavioral support would continue after a stop [3, 5]; and how long the available data run, given that the longest randomized semaglutide weight data reviewed here cover 4 years ^[6]. No published trial in the evidence reviewed here has tested a specific taper schedule for preventing regain, so any tapering plan would come from a prescriber’s judgment rather than trial data.

Sources

1. JAMA. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
2. Diabetes, Obesity and Metabolism. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. 2022.
3. PubMed. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
4. PubMed. Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis.
5. Nature Medicine. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.
6. Nature Medicine. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.
7. PubMed. Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status.
8. New England Journal of Medicine. Once-Weekly Semaglutide in Adults with Overweight or Obesity.
9. PubMed Central. Real-world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic.
10. Prime Therapeutics. GLP-1 Therapy to Treat Obesity Among Members Without Diabetes: Three-Year Persistence and Year-Over-Year Persistence Rate Change. June 25, 2025.
11. PubMed. Discontinuation of Semaglutide Therapy for Obesity Management.
12. PubMed. Weight regain after cessation of medication for weight management: systematic review and meta-analysis.
13. PubMed. Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide.
14. Epic Research. Two Years After Stopping GLP-1s, Most Patients Sustain at Least Some Weight Loss.
15. Medscape Medical News. Real-World Study Finds Over 50% Stop GLP-1s Within 1 Year. September 15, 2025.